PRIA Logo™
119-s-4109119th CongressWALLET

Stem Cell Therapeutic and Research Reauthorization Act of 2026

Sponsored By: Senator Reed, Jack [D-RI]

In Committee

Summary

Modernize funding and management of the National Cord Blood Inventory. This bill would reauthorize the Stem Cell Therapeutic and Research Act as the Stem Cell Therapeutic and Research Reauthorization Act of 2026 and update funding, cord blood inventory standards, transfer authority for units, and the schedule for science reviews through FY2027–FY2031.

Show full summary
  • Families and patients: The bill would aim to preserve access to high-quality cord blood units by replacing a fixed inventory target with a flexible sufficiency standard and authorizing transfers of units if a bank can no longer distribute them.
  • Cord blood banks and transplant programs: It would let the Secretary set inventory size and composition based on current scientific and clinical evidence and allow transfers of units when a bank fails standards or closes.
  • Federal program and funding: The bill would keep the base appropriation at $31.0 million and authorize a new dedicated appropriation of $33.0 million each fiscal year from 2027 through 2031 to support the C.W. Young Cell Transplantation Program.

*This bill would increase federal spending by authorizing about $33.0 million in dedicated funding each year from 2027 through 2031.*

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

More funding for cell transplants

If enacted, the bill would keep the current $31,009,000 base appropriation for the C.W. Bill Young Cell Transplantation Program. If enacted, it would authorize an additional $33,009,000 for each fiscal year 2027 through 2031. If enacted, the extra money would support program operations and activities during those years.

New rules to manage cord blood

If enacted, the bill would replace the fixed 150,000-unit cord blood goal with a flexible "sufficient supply" standard of high-quality units. If enacted, the Secretary would define "high-quality" as units meeting current industry standards and FDA requirements. If enacted, the Secretary could move units from banks that stop operating or fail quality standards to other approved banks. If enacted, the Secretary would manage inventory size and mix to maximize clinical use, preserve genetic diversity, and use federal dollars efficiently. If enacted, the inventory rules would apply for 2027 through 2031 and program reviews would begin one year after enactment, with the first required review three years after enactment and covering cord blood and new technologies.

Sponsors & CoSponsors

Sponsor

Reed, Jack [D-RI]

RI • D

Cosponsors

  • Sen. Scott, Tim [R-SC]

    SC • R

    Sponsored 3/17/2026

  • Sen. Smith, Tina [D-MN]

    MN • D

    Sponsored 3/17/2026

  • Sen. Lankford, James [R-OK]

    OK • R

    Sponsored 3/17/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation